Captured Human RANK, Mouse IgG2a Fc Tag, low endotoxin (Cat. No. RAK-H5251) on CM5 chip via Anti-Mouse antibodies surface can bind Human TNFSF11, Fc Tag (Cat. No. RAL-H5265) with an affinity constant of 0.574 nM as determined in a SPR assay (Biacore T200) (Routinely tested).
Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Denosumab biosimilar(Reliance Life Sciences) | R-TPR-045 | Approved | Reliance Life Sciences | DenosuRel | India | Osteoporosis, Postmenopausal; Bone metastases | Reliance Life Sciences | 2022-02-01 | Bone metastases; Osteoporosis, Postmenopausal | Details |
Denosumab biosimilar (Boan Biopharma/Luye) | LY-01011; BA-1102; BA-6101; LY-06006 | Approved | Shandong Boan Biotechnology Co Ltd, Luye Pharma Group Ltd | Mainland China | Osteoporosis, Postmenopausal | Shandong Boan Biotechnology Co Ltd | 2022-11-10 | Bone metastases; Solid tumours; Osteoporosis; Osteoporosis, Postmenopausal; Neoplasms; Bone Neoplasms; Neoplasm Metastasis | Details | |
Denosumab | NSC-744010; AMG-162; ENZ-215 | Approved | Amgen Inc | Prolia, Xgeva, Pralia, Ranmark | Mainland China | Osteoporosis, Postmenopausal | Amgen Inc | 2010-05-26 | Lung Neoplasms; Prostatic Neoplasms, Castration-Resistant; Feeding and Eating Disorders; Bone Cysts, Aneurysmal; Giant Cell Tumors; Prostatic Neoplasms; Breast Neoplasms; Arthropathy, Neurogenic; Osteosarcoma; Osteogenesis Imperfecta; Giant Cell Tumor of Bone; Breast Diseases; Bone Neoplasms; Multiple Myeloma; Fractures, Bone; Lymphoma; Granuloma, Giant Cell; Carcinoma, Squamous Cell; Lymphoma, Non-Hodgkin; Thyroid Neoplasms; Osteoblastoma; Carcinoma, Non-Small-Cell Lung; Anorexia Nervosa; Crohn Disease; Neoplasm Metastasis; Fibroma; Pain; Hematologic Neoplasms; Endocrine Gland Neoplasms; Kidney Neoplasms; Cataract; Solid tumours; Hematopoietic stem cell transplantation (HSCT); Head and Neck Neoplasms; Osteoporosis; Parathyroid Neoplasms; Carcinoma; Bone Diseases, Metabolic; Fibrous Dysplasia of Bone; Bone metastases; Osteoporosis, Postmenopausal; Chondroblastoma; Colonic Neoplasms; Neoplasms; Hypercalcemia; Kidney Diseases; Arthritis, Rheumatoid; Smoldering Multiple Myeloma; Hodgkin Disease; Carcinoma, Ovari | Details |
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Recombinant human anti-RANKL momoclonal antibody (Qilu Pharmaceutical) | Phase 3 Clinical | Qilu Pharmaceutical Co Ltd | Osteoporosis, Postmenopausal; Neoplasms | Details | |
Recombinant human anti-RANKL antibody (Innovent Biologics) | IBI-307 | Phase 1 Clinical | Innovent Biologics(Suzhou) Co Ltd | Osteoporosis | Details |
Denosumab biosimilar (Intas Biopharmaceuticals) | Phase 3 Clinical | Intas Biopharmaceuticals | Osteoporosis, Postmenopausal | Details | |
Denosumab biosimilar (Alphamab) | KN-012 | Phase 3 Clinical | Osteoporosis, Postmenopausal | Details | |
LZM-004 | LZM-004 | Phase 1 Clinical | Livzon(Group) Pharmaceutical Factory | Bone metastases | Details |
Recombinant human anti-RANKL antibody (Hisun Pharma) | HS629 | Phase 1 Clinical | Zhejiang Hisun Pharmaceutical Co Ltd | Solid tumours; Bone metastases | Details |
Denosumab biosimilar(Fresenius Kabi) | FKS-518 | Fresenius Kabi Swissbiosim Gmbh | Details | ||
GB-223 | GB-223 | Phase 1 Clinical | Genor Biopharma Co Ltd | Solid tumours; Bone metastases; Osteoporosis, Postmenopausal; Giant Cell Tumor of Bone | Details |
CEP-37251 | ART-010; EGX-010; CEP-37251 | Teva | Details | ||
Denosumab biosimilar (AryoGen) | Phase 3 Clinical | Aryogen Biopharma | Osteoporosis | Details | |
KP-46 | KP-46; FFC-11; LX-001; AP-002 | Phase 2 Clinical | University Of Heidelberg, Meram | Solid tumours | Details |
Denosumab biosimilar(Mabxience) | Phase 3 Clinical | Mabxience Sa | Osteoporosis, Postmenopausal | Details | |
Denosumab biosimilar (Samsung Bioepis) | SB-16 | Phase 3 Clinical | Samsung Bioepis Co Ltd | Osteoporosis, Postmenopausal | Details |
MV-088 | MV-088 | Phase 1 Clinical | Kpc Pharmaceuticals Inc | Osteoporosis, Postmenopausal | Details |
Denosumab biosimilar(Alvotech Swiss) | AVT-03 | Phase 3 Clinical | Alvotech Swiss Ag | Osteoporosis, Postmenopausal | Details |
Denosumab biosimilar (Hualan Biological Engineering) | Phase 1 Clinical | Hualan Genetic Engineering Co Ltd | Solid tumours; Osteoporosis, Postmenopausal | Details | |
Denosumab biosimilar(Shanghai Hansoh) | HS-20090; HS-20090-2 | Phase 3 Clinical | Shanghai Hansoh Biomedical Co Ltd, Jiangsu Hansoh Pharmaceutical Group Co Ltd | Solid tumours; Bone metastases; Neoplasms; Osteoporosis, Postmenopausal; Bone Diseases; Hypercalcemia; Multiple Myeloma; Giant Cell Tumor of Bone; Nutritional and Metabolic Diseases | Details |
RGB-14-P | RGB-14-P | Phase 3 Clinical | Gedeon Richter Plc | Osteoporosis, Postmenopausal | Details |
Denosumab biosimiliar (Celltrion) | CT-P41 | Phase 3 Clinical | Celltrion Inc | Osteoporosis, Postmenopausal | Details |
Denosumab biosimilar (Sandoz) | GP-2411 | Phase 3 Clinical | Novartis Pharma Ag, Sandoz | Osteoporosis, Postmenopausal | Details |
Denosumab biosimilar (Henlius ) | HLX-14; HLX14 | Phase 3 Clinical | Shanghai Henlius Biotech Co Ltd | Osteoporosis, Postmenopausal | Details |
This web search service is supported by Google Inc.